Document is current
Any future updates will be listed below
-
Authors
Piontkowski, Austin J.
Mikhaylov, Daniela
Alani, Omar
Orloff, Jeremy
Powers, Camille
Gulati, Nicholas
Ungar, Benjamin
- License Information
-
More Information
Article History
Received: 11 April 2024
Revised: 11 April 2024
Accepted: 26 April 2024
First Online: 25 May 2024
Declarations
:
: BU is an employee of Mount Sinai and has received research funds (grants paid to the institution) from: Incyte, Rapt Therapeutics, and Pfizer. He is also a consultant for Arcutis Biotherapeutics, Bristol Myers Squibb, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, and UCB. The other authors have no conflicts of interest.
: Reviewed and deemed exempt by Icahn School of Medicine at Mount Sinai Institutional Review Board; STUDY-22-00884. The data that support these findings are publicly available and de-identified.
: Not applicable.
: The authors declare no competing interests.
